Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover study of ocrelizumab in multiple sclerosis
NL-OMON59041Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Nov 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59041.